Milestone Pharmaceuticals Inc.

NasdaqGS MIST

Milestone Pharmaceuticals Inc. Revenue Per Share for the year ending December 31, 2023: USD 0.02

Milestone Pharmaceuticals Inc. Revenue Per Share is USD 0.02 for the year ending December 31, 2023, a -80.24% change year over year. Revenue per share indicates revenue generated per share; higher ratios suggest stronger performance and value.
  • Milestone Pharmaceuticals Inc. Revenue Per Share for the year ending December 31, 2022 was USD 0.12, a -67.15% change year over year.
  • Milestone Pharmaceuticals Inc. Revenue Per Share for the year ending December 31, 2021 was USD 0.36, a 0.00% change year over year.
  • Milestone Pharmaceuticals Inc. Revenue Per Share for the year ending December 31, 2020 was USD 0.00, a 0.00% change year over year.
  • Milestone Pharmaceuticals Inc. Revenue Per Share for the year ending December 31, 2019 was USD 0.00, a 0.00% change year over year.
Key data
Date Revenue Per Share Dividend Per Share Free Cash Flow Per Share Return on Assets (ROA)
Market news
Loading...
NasdaqGS: MIST

Milestone Pharmaceuticals Inc.

CEO Mr. Joseph G. Oliveto M.B.A.
IPO Date May 9, 2019
Location Canada
Headquarters 1111 Dr. Frederik-Philips Boulevard
Employees 47
Sector Health Care
Industries
Description

Milestone Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines. The company is developing etripamil, a novel channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate. It has a license and collaboration agreement with Ji Xing Pharmaceuticals to develop and commercialize etripamil prophylactic and therapeutic uses in humans. The company was incorporated in 2003 and is headquartered in Montréal, Canada.

Similar companies

SCPH

scPharmaceuticals Inc.

USD 3.38

-3.70%

CMPX

Compass Therapeutics, Inc.

USD 2.00

2.56%

NAMS

NewAmsterdam Pharma Company N.V.

USD 23.67

-3.70%

CHRS

Coherus BioSciences, Inc.

USD 1.44

-2.04%

DMAC

DiaMedica Therapeutics Inc.

USD 5.02

1.21%

GLUE

Monte Rosa Therapeutics, Inc.

USD 5.56

-1.77%

HOOK

HOOKIPA Pharma Inc.

USD 1.86

4.49%

TERN

Terns Pharmaceuticals, Inc.

USD 4.57

-4.79%

IKT

Inhibikase Therapeutics, Inc.

USD 2.66

0.00%

CGEM

Cullinan Oncology, Inc.

USD 10.01

-9.33%

DAWN

Day One Biopharmaceuticals, Inc.

USD 11.16

-3.46%

StockViz Staff

January 15, 2025

Any question? Send us an email